Mark K. Bennett
YOU?
Author Swipe
View article: Supplementary Data from A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
Supplementary Data from A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors Open
Figures S1-S3 and Supplementary Methods
View article: Data from A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
Data from A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors Open
Purpose:Glutamine is a critical fuel for solid tumors. Interference with glutamine metabolism is deleterious to neoplasia in preclinical models. A phase I study of the oral, first-in-class, glutaminase (GLS) inhibitor telaglenastat was con…
View article: Tactics, learning and the civil-military interface in Europe, 1870–1875
Tactics, learning and the civil-military interface in Europe, 1870–1875 Open
Almost as striking as the totality of German victory in the Franco-Prussian War is the paucity of contemporary observers who anticipated the result – particularly with an earlier, similarly stunning Prussian victory over Austria to judge b…
View article: Writing for Inquiry and Research
Writing for Inquiry and Research Open
Writing for Inquiry and Research guides students through the composition process of writing a research paper. The book divides this process into four chapters that each focus on a genre connected to research writing: the annotated bibliogr…
View article: Supplementary Figure 7 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 7 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 113K, Supplementary Figure S7. Oral dosing of CB-839 results in high exposure in mouse plasma and is well tolerated in immunocompromised mice.
View article: Supplementary Figure 6 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 6 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 100K, Supplementary Figure S6. The basal glutamate to glutamine ratio and the fold change in glutamine and glutamate following CB-839 treatment is greater in TNBC cells than receptor-positive cell lines.
View article: Supplementary Materials and Methods from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Materials and Methods from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 246K, Supplementary Materials and Methods.
View article: Supplementary Figure 5 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 5 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 85K, Supplementary Figure S5. Induction of apoptotic cell death by CB-839.
View article: Supplementary Figure 1 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 1 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDf - 136K, Supplementary Figure S1. CB-839 is a non-competitive inhibitor of rHu-GAC.
View article: Supplementary Figure 4 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 4 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 125K, Supplementary Figure S4. Markers of glutamine utilization are increased in TNBC cell lines relative to receptor-positive cell lines.
View article: Supplementary Figure 7 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 7 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 113K, Supplementary Figure S7. Oral dosing of CB-839 results in high exposure in mouse plasma and is well tolerated in immunocompromised mice.
View article: Data from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Data from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
Glutamine serves as an important source of energy and building blocks for many tumor cells. The first step in glutamine utilization is its conversion to glutamate by the mitochondrial enzyme glutaminase. CB-839 is a potent, selective, and …
View article: Supplementary Figure 3 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 3 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 126K, Supplementary Figure S3. TNBC primary tumors and cell lines have elevated glutaminase (GAC) mRNA levels.
View article: Supplementary Figure 3 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 3 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 126K, Supplementary Figure S3. TNBC primary tumors and cell lines have elevated glutaminase (GAC) mRNA levels.
View article: Supplementary Figure 2 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 2 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 189K, Supplementary Figure S2. CB-839 has potent anti-proliferative activity in TNBC cells that is associated with selective impairment of glutamine utilization.
View article: Supplementary Figure 1 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 1 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDf - 136K, Supplementary Figure S1. CB-839 is a non-competitive inhibitor of rHu-GAC.
View article: Supplementary Figure 6 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 6 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 100K, Supplementary Figure S6. The basal glutamate to glutamine ratio and the fold change in glutamine and glutamate following CB-839 treatment is greater in TNBC cells than receptor-positive cell lines.
View article: Supplementary Materials and Methods from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Materials and Methods from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 246K, Supplementary Materials and Methods.
View article: Data from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Data from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
Glutamine serves as an important source of energy and building blocks for many tumor cells. The first step in glutamine utilization is its conversion to glutamate by the mitochondrial enzyme glutaminase. CB-839 is a potent, selective, and …
View article: Supplementary Figure 2 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 2 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 189K, Supplementary Figure S2. CB-839 has potent anti-proliferative activity in TNBC cells that is associated with selective impairment of glutamine utilization.
View article: Supplementary Figure 4 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 4 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 125K, Supplementary Figure S4. Markers of glutamine utilization are increased in TNBC cell lines relative to receptor-positive cell lines.
View article: Supplementary Figure 5 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Supplementary Figure 5 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Open
PDF - 85K, Supplementary Figure S5. Induction of apoptotic cell death by CB-839.
View article: Supplementary Data from Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial
Supplementary Data from Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial Open
Supplementary Data from Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial
View article: Supplementary Figure from Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial
Supplementary Figure from Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial Open
Supplementary Figure from Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial
View article: Data from Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial
Data from Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial Open
Purpose:Dual inhibition of glucose and glutamine metabolism results in synergistic anticancer effects in solid tumor models. Telaglenastat, an investigational, small-molecule, glutaminase inhibitor, exhibits modest single-agent activity in…
View article: Data from Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
Data from Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events Open
Purpose: Bortezomib (Velcade), a dipeptide boronate 20S proteasome inhibitor and an approved treatment option for multiple myeloma, is associated with a treatment-emergent, painful peripheral neuropathy (PN) in more than 30% of patients. C…
View article: Supplementary Data from Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
Supplementary Data from Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events Open
Supplementary Figures S1-S4; Supplementary Tables S1-S2.
View article: Supplementary Figure from Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial
Supplementary Figure from Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial Open
Supplementary Figure from Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial
View article: Supplementary Data from Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial
Supplementary Data from Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial Open
Supplementary Data from Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial
View article: Supplementary Data from Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
Supplementary Data from Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events Open
Supplementary Figures S1-S4; Supplementary Tables S1-S2.